Role of Immune Cells in Immunosuppressive Drug-Induced Hypertension

描述（由申请人提供）：免疫抑制药物降低移植后器官排斥的发生率和自身免疫性疾病的严重程度；然而，这些药物可引起内皮功能障碍和高血压，这是其使用的主要限制。本研究的目的是阐明免疫抑制药物环孢素A （CsA）和FK506（他克莫司）引起的T细胞改变改变内皮功能和血压调节的免疫学机制。我们将验证CsA-和fk506诱导的有益调节性T细胞（Tregs）的减少和有害Th17细胞的增加有助于内皮功能障碍和高血压的发展的总体假设。为了验证这一假设，我们将追求三个目标。特异性目的1将研究treg来源和Th17细胞来源的细胞因子对内皮功能和血压调节的影响。如果CsA和FK506引起的Tregs减少和Th17细胞增加导致内皮功能障碍和高血压，那么来自这些T细胞亚群的细胞因子应该直接调节内皮功能和血压。具体来说，IL-17应该直接诱导内皮功能障碍和高血压，这应该通过Treg或Treg衍生的细胞因子来预防。特异性Aim 2将确定csa处理和fk506处理小鼠淋巴细胞对内皮功能的直接影响。经CsA或FK506处理的小鼠淋巴细胞可直接引起从对照小鼠分离的内皮细胞和血管的内皮功能障碍。此外，分离的对照内皮细胞和血管在与csa处理或fk506处理的小鼠淋巴细胞孵育后，在抑制Th17细胞或增强Tregs后，应表现出正常的内皮功能。特异性Aim 3将确定淋巴细胞在csa诱导和FK506诱导的高血压中的作用。在csa和fk506治疗的小鼠中，Th17细胞的缺乏和/或treg的增加应该使血压正常化。此外，将csa处理或FK506处理的小鼠的T细胞过继转移到对照小鼠中会引起内皮功能障碍和高血压。为此，我们将在内皮细胞、离体血管和小鼠中使用各种药物和/或遗传扰动Tregs和Th17细胞的组合。完成这些目标将确定CsA和FK506引起的内皮功能障碍和高血压的分子机制，以及可能的治疗方法。

DESCRIPTION (provided by applicant): Immunosuppressive drugs reduce the incidence of organ rejection following transplantation and the severity of autoimmune diseases; however these drugs can cause endothelial dysfunction and hypertension which is a major limitation to their use. The objective of the current proposal is to elucidate the immunological mechanisms by which alterations in T cells caused by the immunosuppressive drugs cyclosporine A (CsA) and FK506 (tacrolimus) alter endothelial function and blood pressure regulation. We will test the overall hypothesis that CsA- and FK506-induced decreases in beneficial regulatory T cells (Tregs) and increases in detrimental Th17 cells contribute to the development of endothelial dysfunction and hypertension. To test this hypothesis we will pursue 3 aims. Specific Aim 1 will examine the effects of Treg-derived and Th17 cell-derived cytokines on endothelial function and blood pressure regulation. If decreased Tregs and increased Th17 cells caused by CsA and FK506 contribute to the endothelial dysfunction and hypertension, then cytokines derived from these T cell subsets should directly modulate endothelial function and blood pressure. Specifically, IL-17 should directly induce endothelial dysfunction and hypertension and this should be prevented by Tregs or Treg- derived cytokines. Specific Aim 2 will determine the direct effects of lymphocytes from CsA-treated and FK506-treated mice on endothelial function. Lymphocytes from mice treated with CsA or FK506 should directly cause endothelial dysfunction in endothelial cells and blood vessels isolated from control mice. Additionally, isolated control endothelial cells and blood vessels should exhibit normal endothelial function following incubation with lymphocytes from CsA-treated or FK506-treated mice following inhibition of Th17 cells or augmentation of Tregs. Specific Aim 3 will determine the role of lymphocytes in CsA-induced and FK506- induced hypertension. Deficiency of Th17 cells and/or augmentation of Tregs should normalize blood pressure in CsA-treated and FK506-treated mice. Additionally, adoptive transfer of T cells from CsA-treated or FK506- treated mice into control mice should cause endothelial dysfunction and hypertension. To this end, we will use various combinations of pharmacologic and/or genetic perturbations of Tregs and Th17 cells in endothelial cells, isolated blood vessels, and mice. Completion of the aims will identify the molecular mechanisms responsible for, as well as possible therapies to prevent, the endothelial dysfunction and hypertension caused by CsA and FK506.